212 related articles for article (PubMed ID: 31488077)
1. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients.
Berger E; Delpierre C; Despas F; Bertoli S; Bérard E; Bombarde O; Bories P; Sarry A; Laurent G; Récher C; Lamy S
BMC Cancer; 2019 Sep; 19(1):883. PubMed ID: 31488077
[TBL] [Abstract][Full Text] [Related]
2. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
Juliusson G; Antunovic P; Derolf A; Lehmann S; Möllgård L; Stockelberg D; Tidefelt U; Wahlin A; Höglund M
Blood; 2009 Apr; 113(18):4179-87. PubMed ID: 19008455
[TBL] [Abstract][Full Text] [Related]
3. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
Lao Z; Yiu R; Wong GC; Ho A
Asia Pac J Clin Oncol; 2015 Mar; 11(1):54-61. PubMed ID: 25545192
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.
Bories P; Bertoli S; Bérard E; Laurent J; Duchayne E; Sarry A; Delabesse E; Beyne-Rauzy O; Huguet F; Récher C
Am J Hematol; 2014 Dec; 89(12):E244-52. PubMed ID: 25195872
[TBL] [Abstract][Full Text] [Related]
6. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
[TBL] [Abstract][Full Text] [Related]
8. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
9. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience.
Tasaki T; Yamauchi T; Matsuda Y; Takai M; Ookura M; Lee S; Tai K; Ikegaya S; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Anticancer Res; 2014 Oct; 34(10):5631-6. PubMed ID: 25275066
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial.
Pongudom S; Phinyo P; Chinthammitr Y; Charoenprasert K; Kasyanan H; Wongyai K; Purattanamal J; Panoi N; Surawong A
Asian Pac J Cancer Prev; 2020 Jan; 21(1):147-155. PubMed ID: 31983177
[TBL] [Abstract][Full Text] [Related]
11. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
13. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
15. Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG.
Owattanapanich W; Utchariyaprasit E; Tantiworawit A; Rattarittamrong E; Niparuck P; Puavilai T; Julamanee J; Saelue P; Chanswangphuwana C; Polprasert C; Limvorapitak W; Kanitsap N; Wanitpongpun C; Nakhakes C; Sriswasdi C; Prayongratana K
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e509-e514. PubMed ID: 30213720
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
[TBL] [Abstract][Full Text] [Related]
17. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia.
El-Jawahri A; Nelson-Lowe M; VanDusen H; Traeger L; Abel GA; Greer JA; Fathi A; Steensma DP; LeBlanc TW; Li Z; DeAngelo D; Wadleigh M; Hobbs G; Foster J; Brunner A; Amrein P; Stone RM; Temel JS
Oncologist; 2019 Feb; 24(2):247-254. PubMed ID: 30139841
[TBL] [Abstract][Full Text] [Related]
18. Selection of elderly acute myeloid leukemia patients for intensive chemotherapy: effectiveness of intensive chemotherapy and subgroup analysis.
Kim DS; Kang KW; Yu ES; Kim HJ; Kim JS; Lee SR; Park Y; Sung HJ; Yoon SY; Choi CW; Kim BS
Acta Haematol; 2015; 133(3):300-9. PubMed ID: 25470986
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
20. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Am J Hematol; 2015 Mar; 90(3):208-14. PubMed ID: 25421221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
